Skip directly to local search Skip directly to A to Z list Skip directly to navigation Skip directly to site content Skip directly to page options
CDC Home

Volume 11, Number 8—August 2005

Research

Spoligotyping and Mycobacterium tuberculosis

Andrea Gori*Comments to Author , Alessandra Bandera*, Giulia Marchetti*, Anna Degli Esposti*, Lidia Catozzi*, Gian Piero Nardi*, Lidia Gazzola*, Giulio Ferrario*, Jan D.A. van Embden†, Dick van Soolingen†, Mauro Moroni*, and Fabio Franzetti*
Author affiliations: *University of Milan, Milan, Italy; †National Institute of Public Health and Environmental Protection, Bilthoven, the Netherlands

Main Article

Figure 1

Clinical and therapeutic implications of spoligotyping results in treating suspected mycobacterial diseases. AFB, acid-fast bacilli; pts, patients; MAC, Mycobacterium avium complex; TB, tuberculosis. *Twenty-five patients did not begin treatment because they did not have clinical and radiologic features of tuberculosis. Four patients died within a few days after admission without receiving any antimycobacterial drug.

Figure 1. . . Clinical and therapeutic implications of spoligotyping results in treating suspected mycobacterial diseases. AFB, acid-fast bacilli; pts, patients; MAC, Mycobacterium avium complex; TB, tuberculosis. *Twenty-five patients did not begin treatment because they did not have clinical and radiologic features of tuberculosis. Four patients died within a few days after admission without receiving any antimycobacterial drug.

Main Article

Top of Page

 

Past Issues

Select a Past Issue:

Art in Science - Selections from Emerging Infectious Diseases
Now available for order



CDC 24/7 – Saving Lives, Protecting People, Saving Money. Learn More About How CDC Works For You…

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO